检索结果-南通市图书馆

国际医学放射学杂志 2009年第2期32卷 186-186页

作者： G.d’Assignies A.Couvelard S.Bahrami M.P.Vullierme P.Hammel o.hentic 朱玉兆 Departments of Radiology and Pathology INSERM Unité 773 CRB3and the Fédération Médico ChirurgicaleBeaujon Hospital

目的前瞻性评价胰腺内分泌肿瘤的多层CT灌注测定与组织学上肿瘤微血管密度的相关性，并确定不同分级的肿瘤其CT灌注参数是否有区别。方法本研究获机构审查委员会批准和知情同意书。

关键词：胰腺内分泌肿瘤 CT灌注预后因素血管发生 CT评价肿瘤微血管密度血流前瞻性评价

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Gemcitabine in elderly patients with advanced pancreatic cancer

引用

World Journal of Gastroenterology 2011年第30期17卷 3497-3502页

作者： olivia hentic Vinciane Rebours Philippe Lévy Philippe Ruszniewski Pascal Hammel Magaly Zappa Chantal Dreyer Eric Raymond Ple des maladies de l'Appareil Digestif Service de PancréatologieHpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Ple des maladies de l’Appareil Digestif Service de PancréatologieHpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Service de Radiologie Hpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Service de Cancérologie Hpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance

AIM： To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHoDS： All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were： performance status 0-2, adequate biological parameters and no serious comorbidities. other patients received best supportive care （BSC）. RESULTS： Thirty-eight patients （53% women, median age 78 years, range 75-84） with pancreatic cancer （metastatic： n = 20, locally advanced： n = 18） were studied. Among them, 30 （79%） were able to receive chemotherapy [median number： 9 infusions （1-45）]. Six patients （23%） had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients （11%） had a partial tumor response, 13 （46%） had a stable disease and 12 （43%） had a tumor progression. Median survival was 9.1 mo （metastatic： 6.9 too, locally advanced： 11.4 too）. CoNCLUSIoN： Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.

关键词： Elderly Pancreas Cancer Gemcitabine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

FoLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

引用

World Journal of Gastroenterology 2012年第33期18卷 4533-4541页

作者： Cindy Neuzillet olivia hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel Service de Gastroentérologie-Pancréatologie Hpital Beaujon 100 Boul-evard du Général Leclerc 92110 Clichy La Garenne AP-HP France Service d'oncologie Médicale Hpital Saint Antoine 184 Rue du Faubourg Saint-Antoine 75012 Paris AP-HP France Unité de Biostatistique et d'Epidémiologie EA 4184 Centre Georges Franois Leclerc 1 Rue du Pr Marion 21079 Dijon France Service d'oncologie Médicale Hpital Beau-jon 100 Boulevard du Général Leclerc 92110 Clichy La Garenne AP-HP France Département d'oncologie Médicale Institut Mutualiste Montsouris 42 Boulevard Jourdan 75014 Paris France

AIM: To evaluate the efficacy and safety of the FoLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHoDS: All consecutive patients with histologically confirmed, metastatic PAC and World Health organiza-tion performance status (PS) ≤ 2 received FoLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FoLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (oS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FoLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FoLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FoLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FoLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median oS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated w

关键词： Pancreatic cancer Pancreatic adenocarcinoma Metastases Chemotherapy 5-fluorouracil Irinotecan Camptothecin FoLFIRI regimen

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：